Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
110.36
-2.11 (-1.88%)
At close: Aug 31, 2026, 4:00 PM EDT
110.75
+0.39 (0.35%)
After-hours: Aug 31, 2026, 7:56 PM EDT
Abbott Laboratories Revenue
Abbott Laboratories had revenue of $12.59B in the quarter ending June 30, 2026, with 13.02% growth. This brings the company's revenue in the last twelve months to $46.59B, up 8.06% year-over-year. In the year 2025, Abbott Laboratories had annual revenue of $44.33B with 5.67% growth.
Revenue (ttm)
$46.59B
Revenue Growth
+8.06%
P/S Ratio
4.10
Revenue / Employee
$405,087
Employees
115,000
Market Cap
190.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 44.33B | 2.38B | 5.67% |
| Dec 31, 2024 | 41.95B | 1.84B | 4.59% |
| Dec 31, 2023 | 40.11B | -3.54B | -8.12% |
| Dec 31, 2022 | 43.65B | 578.00M | 1.34% |
| Dec 31, 2021 | 43.08B | 8.47B | 24.47% |
| Dec 31, 2020 | 34.61B | 2.70B | 8.48% |
| Dec 31, 2019 | 31.90B | 1.33B | 4.34% |
| Dec 31, 2018 | 30.58B | 3.19B | 11.64% |
| Dec 31, 2017 | 27.39B | 6.54B | 31.35% |
| Dec 31, 2016 | 20.85B | 448.00M | 2.20% |
| Dec 31, 2015 | 20.41B | 158.00M | 0.78% |
| Dec 31, 2014 | 20.25B | 590.00M | 3.00% |
| Dec 31, 2013 | 19.66B | 607.00M | 3.19% |
| Dec 31, 2012 | 19.05B | -2.36B | -11.01% |
| Dec 31, 2011 | 21.41B | -13.76B | -39.13% |
| Dec 31, 2010 | 35.17B | 4.40B | 14.31% |
| Dec 31, 2009 | 30.76B | 1.24B | 4.19% |
| Dec 31, 2008 | 29.53B | 3.61B | 13.94% |
| Dec 31, 2007 | 25.91B | 3.44B | 15.30% |
| Dec 31, 2006 | 22.48B | 138.51M | 0.62% |
| Dec 31, 2005 | 22.34B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medtronic | 36.36B |
| Stryker | 25.84B |
| GE HealthCare Technologies | 21.27B |
| Boston Scientific | 21.00B |
| Koninklijke Philips | 20.18B |
| Zimmer Biomet Holdings | 8.51B |
| Edwards Lifesciences | 6.51B |
| Smith & Nephew | 6.30B |
ABT News
- 16 hours ago - Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula - PRNewsWire
- 4 days ago - Abbott’s Amulet 360 device granted CE Mark - TheFly
- 4 days ago - Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke - PRNewsWire
- 6 days ago - FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients - Reuters
- 6 days ago - Abbott receives FDA authorization for Libre Duo 10 Day system - TheFly
- 6 days ago - Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes - PRNewsWire
- 11 days ago - Abbott agrees to $670 million settlement of infant formula cases - Reuters
- 11 days ago - Abbott resolves portion of litigation regarding specialty infant formulas - TheFly